Search

everythinglearnresearchcommunity

for

Search:↓

The user has been using Finasteride for hair loss and is considering adding alphatradiol, stemoxydine, or 2% minoxidil to their regimen. They are concerned that stemoxydine, which shortens the resting phase of hair, might accelerate hair loss in those not using Finasteride by depleting hair cycles without strengthening miniaturized hairs.

The conversation discusses whether stemoxydine needs to be used for life for hair loss treatment. One user suggests that stemoxydine does not require lifelong use and can make hair exit the resting phase faster, but the benefits may be temporary.

TDM-105795 showed promising hair growth results, with higher efficacy than placebo and minimal side effects. It activates dormant hair follicle stem cells and may maintain gains without immediate loss, unlike minoxidil.

The user experienced regrowth and stabilization in hair density using finasteride, minoxidil, a derma roller, and an LLLT helmet, but noticed a recent decline in hair quality. They only take finasteride orally and are unsure about the effectiveness of the LLLT device.

Minoxidil and finasteride can both cause initial hair shedding, but they work differently; minoxidil promotes hair growth, while finasteride improves the hormonal environment. Starting finasteride after minoxidil may trigger additional shedding, but it often leads to improved regrowth.

PP405 is a potential hair loss treatment showing promise, especially for men with severe balding. Some are hopeful it will be a game-changer for those who cannot tolerate finasteride or minoxidil, despite skepticism about the outcomes.

A user is advocating for Phase 3 trials of the hair loss treatment PP405 to be conducted in Germany, citing benefits like a diverse patient base and faster access for European patients. Despite skepticism about the petition's influence, the user believes it can demonstrate significant interest and potentially influence strategic decisions.

The conversation discusses the effectiveness of RU58841 for hair loss compared to pyrilutamide, which failed to show significant hair regrowth in trials. Some users report personal side effects with RU58841 and question the criteria for success in hair loss treatments.

KPV, a peptide patented by L'Oreal, may promote hair growth and reduce hair loss by extending the anagen phase and has anti-inflammatory properties. It could be combined with treatments like minoxidil for enhanced effects.

The shed phase from using finasteride and minoxidil can vary, with some experiencing noticeable hair loss and others having minimal shedding. Despite initial shedding, many users report eventual hair regrowth and improvement, making the treatment worthwhile.

Finasteride can cause initial hair shedding as part of the treatment process, which is normal and often leads to regrowth of healthier hair. Users discuss experiencing multiple shedding phases and emphasize patience, as results can take several months to become noticeable.

PP405 is not a cure for hair loss but may reactivate dormant hair follicles, similar to minoxidil. It is unlikely to help with miniaturized or vellus hairs and is still in trial phases, with availability expected around 2030.

PP405 is a promising molecule that may reactivate dormant hair follicles, potentially offering a new treatment for hair loss. It is in phase 2 trials, with possible availability between 2027 and 2030.

PP405 is in phase 2 trials for hair loss, with discussions on its cost and effectiveness compared to minoxidil and finasteride. Users are skeptical about its efficacy and timeline, with hopes for market release by 2027.

PP405 may promote short-term hair growth by pushing follicles into the growth phase, but concerns exist about long-term effects due to lack of rest phases. Users discuss various treatments like finasteride, minoxidil, spironolactone, alfatradiol, and investigational drugs like KX-826 and GT20029 for hair maintenance and regrowth.

Increased hair shedding after starting Dutasteride is normal and indicates treatment efficacy, as it triggers a synchronized shedding phase to make way for stronger hair growth. It is advised to continue with the current treatment plan and assess results in 9 to 12 months.

A user reported losing hair after 7 months of using oral minoxidil, finasteride, and dutasteride, but others reassured that this is likely just a shedding phase where old hairs fall out to make way for new growth. Some users experience sheds every 7-8 months and suggest staying consistent with treatment.

The user has been using minoxidil daily, finasteride three times a week, and ketoconazole 1-3 times a week for a year to treat hair loss, resulting in noticeable hair regrowth at the hairline and temples, with minor side effects like itching and dandruff. They started with minoxidil a month before the other treatments and experienced an initial shedding phase for about six weeks.

Switching to Dutasteride worsened hair condition, causing shedding and inflammation. The user will continue Dutasteride until 18 months before possibly switching back to Finasteride, while using oral Minoxidil.

Redensyl is a plant-based treatment that may support hair regrowth by reactivating dormant follicles and improving hair density, especially in early-stage thinning. It is not a miracle cure and results vary; it is less proven than Minoxidil or Finasteride and may cause scalp irritation.

Hair loss prevention and regrowth regimen includes finasteride, oral minoxidil, stemoxydine, hair growth serum, derma rolling, and ketocanazole shampoo. Users discuss efficacy, safety, and personal experiences with treatments.

The user is considering adding Stemoxydine to their hair loss regimen, as they already use topical finasteride with rosemary and cannot use Minoxidil. They are seeking feedback on Stemoxydine and Alphatradiol, and another user mentions 2-deoxy-d-ribose as a potential option.

Hair loss treatments include topical and oral minoxidil, low-level laser light therapy, and peptide serums. Bryan Johnson avoids finasteride and dutasteride due to potential side effects, focusing instead on his own protocol with these treatments.

The conversation is about hair regrowth using topical finasteride, minoxidil, and keto spray, along with oral Saw Palmetto, Lustriva complex, collagen, and microneedling. Users discuss their experiences with these treatments, noting improvements in hair density and color, with some experiencing mild side effects.

Hair loss in men is primarily caused by androgenetic alopecia, with treatments like finasteride and dutasteride often recommended. Other causes include stress, nutritional deficiencies, medications, and scalp infections.

Hair follicles are mostly dormant but can be reactivated with treatments like minoxidil, finasteride, and microneedling. A new drug, PP405, shows promise for hair regrowth but may not be available until 2027-2028.

A 38-year-old female is experiencing hair loss despite having almost undetectable DHT levels after using dutasteride. Suggestions include checking for PCOS, thyroid issues, adjusting diet, considering the impact of birth control, and trying treatments like tretinoin, redensyl, retinol, and minoxidil with derma stamping.

Hair loss varies due to genetic sensitivity to DHT and other factors. Treatments discussed include finasteride, minoxidil, RU58841, and microneedling.

Shedding is common when using finasteride and minoxidil, and it typically stabilizes after a few months, with potential regrowth following. Users report varying experiences, but shedding is generally seen as a normal part of the treatment process.

The user has been using topical minoxidil and finasteride for hair loss, with some regrowth at the temples but continued hairline thinning. The dermatologist suggested possible telogen effluvium due to stress and deficiencies, prescribed oral minoxidil, and may consider dutasteride if the condition doesn't improve by January 2026.